Últimas noticias sobre Nanobiotix (NASDAQ:NBTX) Bolsa

Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix SA

Telsey Advisory Group analyst Joseph Feldman maintains Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Outperform and maintains $455 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Home Depot, Maintains $455 Price Target

GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $(0.06) by 900 percent. This is a 277.78 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $375.26 million which missed the analyst consensus estimate of $2.80 billion by 86.58 percent. This is a 3.13 percent increase over sales of $363.89 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GDS Holdings Q1 EPS $0.48 Beats $(0.06) Estimate, Sales $375.26M Miss $2.80B Estimate

Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) (the "Company") announced today that its subsidiaries, RHP Hotel Properties, LP (the "Operating Partnership") and RHP Finance Corporation (together with the Operating Partnership, the "Issuers"), intend to offer, in a private placement, subject to market and other conditions, up to $600 million aggregate principal amount of senior notes due 2033 (the&nbsp;"Notes"). The Notes will be senior unsecured obligations of the Issuers and guaranteed by the Company and its subsidiaries that guarantee the Operating Partnership's existing credit facility, 4.750% senior unsecured notes due 2027, 7.250% senior unsecured notes due 2028, 4.500% senior unsecured notes due 2029 and 6.500% senior unsecured notes due 2032.
The Operating Partnership intends to use the net proceeds of the offering to fund a portion of the approximately $865 million purchase price for the previously announced pending acquisition of the JW Marriott Phoenix Desert Ridge Resort &amp; Spa located in Phoenix, Arizona (the "Desert Ridge Acquisition") and to pay related fees and expenses of the Desert Ridge Acquisition. The balance of the purchase price of the Desert Ridge Acquisition will be funded with a combination of the net proceeds of an underwritten registered public offering of 2,600,000 shares of common stock at a public offering price of $96.20 per share, which priced on May 19, 2025 (the "Common Stock Offering"), and cash on hand.

Ryman Hospitality Properties' Operating Partnership Intends To Offer Up To $600M Aggregate Principal Amount Of Senior Notes Due 2033

Canaccord Genuity analyst Maria Ripps maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $700 to $775.

SPOT

Canaccord Genuity Maintains Buy on Spotify Technology, Raises Price Target to $775

CACI International Inc ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.nyse.com%2Fquote%2FXNYS%3ACACI&amp;,%20esheet=54256704&amp;,%20newsitemid=20250519426581&amp;,%20lan=en-US&amp;,%20anchor=NYSE%3A+CACI&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">CACI</a>) announced today that it has commenced an offering (the "Offering") of $750 million in aggregate principal amount of unsecured senior notes due 2033 (the "2033 Notes"). CACI intends to use the net proceeds from the Offering to partially repay amounts outstanding under its revolving credit facility.
The 2033 Notes will be guaranteed on a senior unsecured basis by all of CACI's subsidiaries that are borrowers or guarantors under CACI's senior credit facilities.

Offerings

CACI

CACI International Commences Offering Of $750M In Aggregate Principal Amount Of Unsecured Senior Notes Due 2033

Canaccord Genuity analyst Maria Ripps maintains Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) with a Buy and raises the price target from $58 to $70.

Canaccord Genuity Maintains Buy on Life360, Raises Price Target to $70

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $10 price target.

Reiteration

ATAI

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target

The U.S. Department of Transportation (DOT) is expected to declare that Corporate Average Fuel Economy or CAFE regulations implemented under the previous Biden administration exceeded the government's legal authority.
What Happened: Sean Duffy, the U.S. Transportation Secretary, said in a statement that the previous Biden administration "illegally used CAFE standards as a backdoor electric vehicle mandate – driving the price of cars up," Reuters reported on Tuesday.
This comes in as last year, over 120 House Republicans made similar comments about how the National Highway Traffic Safety Administration exceeded its authority and introduced regulations resulting in a de-facto EV mandate. NHTSA "accounted for EVs in its regulatory baseline and factored that baseline into its determination of the maximum achievable CAFE standards," they said.
The agency had last year shared that the rule would decrease Gas consumption by 64 billion gallons and cut emissions by 659 million metric tons. However, it did acknowledge that prices of some vehicles could go up.
The NHTSA had earlier shared in June that it would increase the CAFE requirements to 50.4 miles per gallon, the report suggests.
Why It Matters: House Republicans had earlier proposed to <a href="https://www.benzinga.com/tech/25/05/45277309/house-gop-representatives-want-to-axe-federal-ev-credit-amid-trumps-tax-cuts-report">axe the federal EV credit </a>offered on all EV purchases in the U.S., in a move that was opposite to calls by U.S. automakers who proposed <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">a gradual phasing out</a> of the credit instead.
Elsewhere, EV adoption is growing in the U.S. as data suggests the sector experienced a <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">10.6% YoY growth</a> and several automakers are experiencing triple-digit percentage growth in EV sales in Q1 2025.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45512512/tesla-robotaxi-rival-waymo-announces-california-expansion-as-autonomous-taxi-race-heats-up">Tesla Robotaxi Rival Waymo Announces California Expansion As Autonomous Taxi Race Heats Up</a></li>
</ul>
Photo Courtesy: Natee Meepian On Shutterstock

Government

Regulations

Politics

US Transportation Secretary Says Biden-Era Fuel Economy Standards Exceeded Legal Authority, Calls It 'Backdoor EV Mandate'

Merit's updated full-year 2025 financial guidance now reflects the projected impacts of the Biolife acquisition from the merger effective date of May 20, 2025 through December 31, 2025. Merit is otherwise reaffirming prior full-year 2025 financial guidance previously announced on April 24, 2025.

Guidance

MMSI

Merit Medical Systems Now Sees FY25 Net Sales Of $1.480B - $1.501B Vs Prior Guidance Range Of $1.470B - $1.490B; Now Expects FY25 Non-GAAP EPS Of $3.28-$3.41 Vs Prior Outlook Of $3.29-$3.42

Barrington Research analyst Vincent Colicchio maintains Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Outperform and maintains $164 price target.

NSIT

Barrington Research Maintains Outperform on Insight Enterprises, Maintains $164 Price Target

<ul>
<li>Acquired business offers the StatSeal&#xAE; and WoundSeal&#xAE; products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.</li>
<li>Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile</li>
<li>Merit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition</li>
</ul>
Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. ("Biolife") in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.
The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.

Merit Medical Systems Acquires Biolife Delaware In $120M Merger Transaction

Bowman Consulting Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services and program management firm, has been awarded a $1.3 million contract from the Aerotropolis Area Coordination Metropolitan District (the "District") for the design and development of ATEC Parkway, a two-mile roadway in The Aurora Highlands, located in Aurora, Colorado.
Under the contract, Bowman is designing roadway plans and profiles, drainage studies, water and storm utilities design and stormwater management plans, in addition to providing project management and construction documentation. Bowman serves as program manager and designer for more than $500 million in infrastructure projects in The Aurora Highlands, the largest community development in the Denver metro area, through which the ATEC Parkway transits.

BWMN

Bowman Consulting Group Bags $1.3M Contract From Aerotropolis Area Coordination Metropolitan District For Design, Development Of ATEC Parkway In Aurora Highlands, Colorado

Wells Fargo analyst Michael Sison downgrades Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Overweight to Equal-Weight and lowers the price target from $95 to $76.

Downgrades

Wells Fargo Downgrades Westlake to Equal-Weight, Lowers Price Target to $76

Wells Fargo analyst Michael Turrin initiates coverage on SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) with a Overweight rating.

Initiation

Wells Fargo Initiates Coverage On SAP with Overweight Rating

William Blair analyst Jake Roberge initiates coverage on OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Outperform rating.

William Blair Initiates Coverage On OneStream with Outperform Rating

Board acted in response to substantial accumulation of stock by BBRC
Protects long-term value for all shareholders
REYNOLDSBURG, Ohio, May 20, 2025 (GLOBE NEWSWIRE) -- Victoria's Secret &amp; Co. ("VS&amp;Co" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) today announced that its Board of Directors (the "Board") has approved the adoption of a limited-duration shareholder rights plan ("Rights Plan") to protect the best interests of all VS&amp;Co shareholders. The Rights Plan is effective immediately and expires in one year.
The Board, in consultation with its independent advisors, adopted the Rights Plan in response to the substantial accumulation of shares of VS&amp;Co's common stock by BBRC International Pte Limited, an entity controlled by Brett Blundy (collectively with their affiliates, "BBRC"). In deciding to adopt the Rights Plan, the Board considered, among other things, that:
<ul>
<li>Starting in March 2025, BBRC began increasing its position in VS&amp;Co to approximately 13% of the outstanding shares;</li>
<li>After nearly two years of reporting its beneficial ownership as a "passive investor" on Schedule 13G, in February 2024, BBRC began reporting on a Schedule 13D;</li>
<li>BBRC made acquisitions of the Company's common stock in violation of U.S. antitrust law for nearly three years by failing to file forms required under the Hart-Scott-Rodino Act and observe the regulatory waiting period, and now has made corrective filings that will enable BBRC to acquire up to 49.99% of the Company's voting stock once the waiting period has expired, which we expect will be at 11:59 p.m., Eastern Time, on May 21, 2025;</li>
<li>BBRC has a track record of acquiring controlling interests in retail companies; and</li>
<li>BBRC recently launched a new business described as a global lingerie, sleepwear and beauty brand.</li>
</ul>
The Board also took note of the current period of substantial market dislocation in the retail sector and its potential impact on the trading value of the Company's shares, which the Board does not believe reflects the inherent value of VS&amp;Co's business or its long-term prospects.

VSCO

Victoria's Secret Board Approves Adoption Of Limited-Duration Shareholder Rights Plan, Effective Immediately And Expires In One Year

Needham analyst Scott Berg reiterates Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>) with a Buy and maintains $16 price target.

AMPL

Needham Reiterates Buy on Amplitude, Maintains $16 Price Target

UBS analyst Dan Leonard upgrades Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) from Neutral to Buy and lowers the price target from $1530 to $1350.

Upgrades

UBS Upgrades Mettler-Toledo Intl to Buy, Lowers Price Target to $1350

DeFi Technologies Inc. (the "Company" or "DeFi Technologies") ((<a href="https://c212.net/c/link/?t=0&amp;,%20l=en&amp;,%20o=4431677-1&amp;,%20h=3106281585&amp;,%20u=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fdeft&amp;,%20NASDAQ:%3Ca%20class=">DEFT</a>) (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431677-1&amp;h=3424210174&amp;u=https%3A%2F%2Fwww.cboe.com%2Fca%2Fequities%2Fsecurities%2FDEFI%2F%23!%2Fmarket-depth&amp;a=CBOE+CA%3A+DEFI">CBOE CA: DEFI</a>) (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431677-1&amp;h=537948592&amp;u=https%3A%2F%2Fwww.boerse-frankfurt.de%2Fequity%2Fdefi-technologies-inc-1&amp;a=GR%3A+R9B">GR: R9B</a>), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"), is pleased to announce a strategic joint venture and foundational equity investment in Fire Labs, Inc. ("Fire Labs"), a next-generation stablecoin infrastructure provider incubated and backed by America First Technology ("AFT"). As part of the initiative, Fire Labs will integrate with Kraken Embed, the institutional crypto infrastructure platform from Kraken, to support secure and scalable adoption of its regulated, bank-issued stablecoin.
<ul>
<li>Strategic Joint Venture to Launch Regulated Stablecoin: DeFi Technologies has entered into a joint venture and made a lead equity investment in Fire Labs, a stablecoin infrastructure provider backed by America First Technology ("AFT"). This partnership marks DeFi Technologies' entry into the Real-World Asset ("RWA") sector through the development of a fully regulated, USD-backed stablecoin issued directly by a U.S. chartered bank.</li>
<li>Kraken Integration to Accelerate Institutional Access: To support secure and scalable adoption, Fire Labs will integrate with Kraken Embed—Kraken's modular crypto infrastructure platform—enabling seamless, regulated access to the stablecoin within institutional and enterprise platforms.</li>
<li>GENIUS Act Momentum: The initiative aligns with growing regulatory support in the U.S., including the pending GENIUS Act—a bipartisan bill advancing through Congress to establish a clear federal framework for fiat-backed stablecoins issued by regulated institutions.</li>
<li>Overcollateralized Infrastructure and Revenue Model: Fire Labs' stablecoin will be backed by 105% reserves, exceeding regulatory requirements to ensure stability and trust. A companion yield-bearing token will offer compliant, bank-backed returns tailored for institutional investors. DeFi Technologies will generate revenue through trading fees, yield participation, and broader integration across its business lines.</li>
<li>Minority Investment in AFT: DeFi Technologies has also completed a minority 19.5% investment in CH Technical Solutions SA, operating as AFT.</li>
</ul>

DEFT

DeFi Technologies Announces Strategic JV And Foundational Equity Investment In Fire Labs; Kraken Joins As Strategic Integration Partner To Support Scalable Adoption Of Regulated, Bank-Issued Stablecoin

FTI Consulting Technology Teams Up With BigID To Enhance Data Management Privacy Compliance And Risk Mitigation For Enterprise Clients

Health Care

Press Releases

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Contracts

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Comments

Nanobiotix

Noticias

Últimas noticias sobre Nanobiotix (NASDAQ:NBTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL